Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.049
Sell
RSI(14)
24.198
Sell
STOCH(KDJ)(9,3,3)
7.484
Oversold
ATR(14)
0.050
Low Volatility
CCI(14)
-192.622
Sell
Williams %R
92.961
Oversold
TRIX(12,20)
-1.102
Sell
StochRSI(14)
0.000
Oversold
Search
Longeveron Inc
LGVNAdd to Watchlist
0.670USD
-0.032-4.57%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
20.88MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Longeveron Inc
Currency: USD Updated: 2026-05-15Key Insights
Longeveron Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 167 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.11.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Longeveron Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Longeveron Inc Highlights
StrengthsRisks
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 69.11% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.20M.
Fairly Valued
The company’s latest PE is -0.52, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.25M shares, increasing 33.51% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.93.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.362
Target Price
+805.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Longeveron Inc is 6.03, ranking 291 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 365.00K, representing a year-over-year decrease of 39.47%, while its net profit experienced a year-over-year decrease of 33.40%.
Score
Financials
7.86
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.24
Operational Efficiency
2.84
Growth Potential
5.12
Shareholder Returns
7.08
Longeveron Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Longeveron Inc is 8.53, ranking 40 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.52, which is -1421.38% below the recent high of 6.86 and -835.08% above the recent low of -4.85.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 167/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Longeveron Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 10.45 and a low of 3.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.362
Target Price
+805.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Longeveron Inc
LGVN
3
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Longeveron Inc is 3.53, ranking 364 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.98 and the support level at 0.51, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.743
Sell
MA10
0.801
Sell
MA20
0.868
Sell
MA50
0.937
Sell
MA100
0.746
Sell
MA200
0.772
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Longeveron Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 8.08%, representing a quarter-over-quarter decrease of 6.29%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Longeveron Inc is 2.54, ranking 211 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-0.38
VaR
+9.64%
240-Day Maximum Drawdown
+72.21%
240-Day Volatility
+115.85%
Return
Best Daily Return
60 days
+68.27%
120 days
+68.27%
5 years
+181.16%
Worst Daily Return
60 days
-11.71%
120 days
-11.71%
5 years
-46.62%
Sharpe Ratio
60 days
+1.08
120 days
+0.66
5 years
+0.15
Risk Assessment
Maximum Drawdown
240 days
+72.21%
3 years
+98.65%
5 years
+99.89%
Return-to-Drawdown Ratio
240 days
-0.64
3 years
-0.33
5 years
-0.20
Skewness
240 days
+2.63
3 years
+5.14
5 years
+8.06
Volatility
Realised Volatility
240 days
+115.85%
5 years
+146.98%
Standardised True Range
240 days
+11.53%
5 years
+554.72%
Downside Risk-Adjusted Return
120 days
+201.54%
240 days
+201.54%
Maximum Daily Upside Volatility
60 days
+259.21%
Maximum Daily Downside Volatility
60 days
+72.88%
Liquidity
Average Turnover Rate
60 days
+40.54%
120 days
+21.41%
5 years
--
Turnover Deviation
20 days
-87.67%
60 days
+58.58%
120 days
-16.27%
Peer Comparison
Biotechnology & Medical Research
Longeveron Inc
LGVN
5.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
